Bruker (BRKR) Stock Forecast & Price Target

Compare

472 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BRKR Analyst Ratings

Moderate Buy

7 Buy

4 Hold

1 Sell

Based on 12 analysts giving stock ratings to

Bruker

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BRKR Stock 12 Month Forecast

Average Price Target

$53.36

▲(10.27% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Bruker in the last 3 months. The average price target is $53.36 with a high forecast of $60.00 and a low forecast of $40.00. The average price target represents a 10.27% change from the last price of $48.39.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"32":"$32","61":"$61","39.25":"$39.3","46.5":"$46.5","53.75":"$53.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":53.36,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$53.36</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$40.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[32,39.25,46.5,53.75,61],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.11,48.10153846153846,49.09307692307692,50.08461538461538,51.076153846153844,52.067692307692305,53.059230769230766,54.050769230769234,55.042307692307695,56.033846153846156,57.02538461538462,58.01692307692308,59.00846153846154,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.11,47.59076923076923,48.07153846153846,48.55230769230769,49.03307692307692,49.51384615384615,49.994615384615386,50.47538461538461,50.956153846153846,51.43692307692308,51.917692307692306,52.39846153846154,52.879230769230766,{"y":53.36,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,47.11,46.56307692307692,46.01615384615385,45.46923076923077,44.92230769230769,44.37538461538462,43.82846153846154,43.28153846153846,42.73461538461538,42.18769230769231,41.64076923076923,41.09384615384616,40.54692307692308,{"y":40,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":58.329,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.862,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.986,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.223,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.197,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.587,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.792,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.892,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":33.892,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.683,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 42, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.899,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 44, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.81,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.11,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 33, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$53.36

Lowest Price Target$40.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick B Donnelly

Citi

$40→$53

Hold

9.53%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Bruker (NASDAQ: BRKR)

Michael Ryskin

Bank of America Securities

$60

Buy

23.99%

Upside

Reiterated

01/12/26

Bruker: Solid Q4 Momentum and Reaffirmed 2026 Targets Underpin Buy Rating and Upside Potential

Daniel Brennan

TD Cowen

$42→$53

Hold

9.53%

Upside

Reiterated

01/07/26

Bruker price target raised to $53 from $42 at TD CowenBruker price target raised to $53 from $42 at TD Cowen

Subbu Nambi

Guggenheim

$45→$53

Buy

9.53%

Upside

Reiterated

01/05/26

Bruker price target raised to $53 from $45 at GuggenheimBruker price target raised to $53 from $45 at Guggenheim

Brandon Couillard

Wells Fargo

$48→$55

Buy

13.66%

Upside

Reiterated

12/15/25

Bruker price target raised to $55 from $48 at Wells FargoBruker price target raised to $55 from $48 at Wells Fargo

Luke Sergott

Barclays

$45→$55

Buy

13.66%

Upside

Reiterated

12/15/25

Bruker (BRKR) Receives a Buy from Barclays

Casey Woodring

J.P. Morgan

$50→$55

Buy

13.66%

Upside

Reiterated

12/15/25

Bruker price target raised to $55 from $50 at JPMorganBruker price target raised to $55 from $50 at JPMorgan

Doug Schenkel

Wolfe Research

$60

Buy

23.99%

Upside

Upgraded

12/10/25

Bruker upgraded to Outperform from Peer Perform at Wolfe ResearchBruker upgraded to Outperform from Peer Perform at Wolfe Research

Evie Koslosky

Goldman Sachs

$40

Sell

-17.34%

Downside

Initiated

12/09/25

Bruker initiated with a Sell at Goldman SachsBruker initiated with a Sell at Goldman Sachs

Natalya Davies

Rothschild & Co Redburn

$60

Buy

23.99%

Upside

Reiterated

11/20/25

Bruker initiated with a Buy at Rothschild & Co RedburnBruker initiated with a Buy at Rothschild & Co Redburn

Dan Leonard

UBS

$40→$43

Hold

-11.14%

Downside

Reiterated

11/04/25

Bruker price target raised to $43 from $40 at UBSBruker price target raised to $43 from $40 at UBS

Jack Meehan

Nephron

Hold

―

Upgraded

11/03/25

Bruker upgraded to Hold from Sell at Nephron ResearchBruker upgraded to Hold from Sell at Nephron Research

Puneet Souda

Leerink Partners

Buy

―

Reiterated

09/07/25

Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives

Daniel Arias

Stifel Nicolaus

$48→$40

Hold

-17.34%

Downside

Reiterated

08/05/25

Bruker price target lowered to $40 from $48 at StifelBruker price target lowered to $40 from $48 at Stifel

Tycho Peterson

Jefferies

$70→$60

Buy

23.99%

Upside

Reiterated

08/04/25

Bruker price target lowered to $60 from $70 at JefferiesBruker price target lowered to $60 from $70 at Jefferies

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick B Donnelly

Citi

$40→$53

Hold

9.53%

Upside

Reiterated

01/15/26

Analysts Offer Insights on Healthcare Companies: Boston Scientific (NYSE: BSX) and Bruker (NASDAQ: BRKR)

Michael Ryskin

Bank of America Securities

$60

Buy

23.99%

Upside

Reiterated

01/12/26

Bruker: Solid Q4 Momentum and Reaffirmed 2026 Targets Underpin Buy Rating and Upside Potential

Daniel Brennan

TD Cowen

$42→$53

Hold

9.53%

Upside

Reiterated

01/07/26

Bruker price target raised to $53 from $42 at TD CowenBruker price target raised to $53 from $42 at TD Cowen

Subbu Nambi

Guggenheim

$45→$53

Buy

9.53%

Upside

Reiterated

01/05/26

Bruker price target raised to $53 from $45 at GuggenheimBruker price target raised to $53 from $45 at Guggenheim

Brandon Couillard

Wells Fargo

$48→$55

Buy

13.66%

Upside

Reiterated

12/15/25

Bruker price target raised to $55 from $48 at Wells FargoBruker price target raised to $55 from $48 at Wells Fargo

Luke Sergott

Barclays

$45→$55

Buy

13.66%

Upside

Reiterated

12/15/25

Bruker (BRKR) Receives a Buy from Barclays

Casey Woodring

J.P. Morgan

$50→$55

Buy

13.66%

Upside

Reiterated

12/15/25

Bruker price target raised to $55 from $50 at JPMorganBruker price target raised to $55 from $50 at JPMorgan

Doug Schenkel

Wolfe Research

$60

Buy

23.99%

Upside

Upgraded

12/10/25

Bruker upgraded to Outperform from Peer Perform at Wolfe ResearchBruker upgraded to Outperform from Peer Perform at Wolfe Research

Evie Koslosky

Goldman Sachs

$40

Sell

-17.34%

Downside

Initiated

12/09/25

Bruker initiated with a Sell at Goldman SachsBruker initiated with a Sell at Goldman Sachs

Natalya Davies

Rothschild & Co Redburn

$60

Buy

23.99%

Upside

Reiterated

11/20/25

Bruker initiated with a Buy at Rothschild & Co RedburnBruker initiated with a Buy at Rothschild & Co Redburn

Dan Leonard

UBS

$40→$43

Hold

-11.14%

Downside

Reiterated

11/04/25

Bruker price target raised to $43 from $40 at UBSBruker price target raised to $43 from $40 at UBS

Jack Meehan

Nephron

Hold

―

Upgraded

11/03/25

Bruker upgraded to Hold from Sell at Nephron ResearchBruker upgraded to Hold from Sell at Nephron Research

Puneet Souda

Leerink Partners

Buy

―

Reiterated

09/07/25

Bruker Positioned for Recovery and Growth Amid Financial Maneuvering and Strategic Initiatives

Daniel Arias

Stifel Nicolaus

$48→$40

Hold

-17.34%

Downside

Reiterated

08/05/25

Bruker price target lowered to $40 from $48 at StifelBruker price target lowered to $40 from $48 at Stifel

Tycho Peterson

Jefferies

$70→$60

Buy

23.99%

Upside

Reiterated

08/04/25

Bruker price target lowered to $60 from $70 at JefferiesBruker price target lowered to $60 from $70 at Jefferies

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Bruker

3 Months

xxx

Success Rate

6/11 ratings generated profit

Average Return

+2.81%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 54.55% of your transactions generating a profit, with an average return of +2.81% per trade.

1 Year

Luke SergottBarclays

Success Rate

9/11 ratings generated profit

Average Return

+20.70%

reiterated a buy rating last month

Copying Luke Sergott's trades and holding each position for 1 Year would result in 81.82% of your transactions generating a profit, with an average return of +20.70% per trade.

2 Years

xxx

Success Rate

9/11 ratings generated profit

Average Return

+25.39%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 81.82% of your transactions generating a profit, with an average return of +25.39% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BRKR Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BRKR has received 9 Buy Ratings, 33 Hold Ratings, and 2 Sell Ratings. BRKR average Analyst price target in the past 3 months is 53.36.

Each month's total comprises the sum of three months' worth of ratings.

BRKR Financial Forecast

BRKR Earnings Forecast

Next quarter’s earnings estimate for BRKR is $0.65 with a range of $0.62 to $0.67. The previous quarter’s EPS was $0.45. BRKR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year BRKR has Performed in-line its overall industry.

BRKR Sales Forecast

Next quarter’s sales forecast for BRKR is $958.95M with a range of $952.51M to $967.50M. The previous quarter’s sales results were $860.50M. BRKR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year BRKR has Performed in-line its overall industry.

BRKR Stock Forecast FAQ

What is BRKR’s average 12-month price target, according to analysts?

Based on analyst ratings, Bruker Corp’s 12-month average price target is 53.36.

What is BRKR’s upside potential, based on the analysts’ average price target?

Bruker Corp has 10.27% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BRKR a Buy, Sell or Hold?

Bruker Corp has a consensus rating of Moderate Buy which is based on 7 buy ratings, 4 hold ratings and 1 sell ratings.

What is Bruker Corp’s price target?

The average price target for Bruker Corp is 53.36. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $40.00. The average price target represents 10.27% Increase from the current price of $48.39.

What do analysts say about Bruker Corp?

Bruker Corp’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of BRKR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Bruker (BRKR) Stock Forecast & Price Target

BRKR Analyst Ratings

BRKR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Bruker

BRKR Analyst Recommendation Trends

BRKR Financial Forecast

BRKR Earnings Forecast

BRKR Sales Forecast

BRKR Stock Forecast FAQ

Detailed List of Analyst Forecasts